773031-79-1

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
2-METHYL-5,6-DIHYDRO-4H-PYRROLO[3,4-D]THIAZOLE is used as a key component in the development of new pharmaceuticals due to its potential biological and pharmacological properties. It is particularly valued for its role in the creation of therapeutic agents for various medical conditions.
Used in Industrial Synthesis:
In the industrial sector, 2-METHYL-5,6-DIHYDRO-4H-PYRROLO[3,4-D]THIAZOLE is used as a precursor in the synthesis of other organic compounds. Its chemical structure makes it a valuable building block for creating a range of different products, contributing to the diversity of applications it can be found in.

InChI:InChI=1S/C6H8N2S/c1-4-8-5-2-7-3-6(5)9-4/h7H,2-3H2,1H3

Upstream product

• 170456-88-9 2-methyl-5-(toluene-4-sulfonyl)-4,5,6,6a-tetrahydropyrrolo<4,3-d>thiazol-3a-ol 
• 170456-89-0 2-methyl-5-(toluene-4-sulfonyl)-4,6-dihydro-5H-pyrrolo<3,4-d>thiazole 

Relevant academic research and scientific papers

HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES

Disclosed are compounds of Formula Gl (structurally represented): where "RG3" "Rd1" to "Rd4", "n", "m", "p", "W", "X", "Y", and "Z" are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER

Disclosed are compounds of heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine herein, which have specific binding on an A2A-receptor and are useful for quantifying in vivo receptor-site occupancy of various compounds which have an affinity for binding to an A2A-receptor.

AMINOCYCLOHEXANES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

The present invention is directed to novel substituted aminocyclohexanes of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.